Impact of KRASG12D subtype and concurrent pathogenic mutations on advanced non-small cell lung cancer outcomesEnrique Caballé‐Perez(Instituto Nacional de Cancerología), Óscar Arrieta(Instituto Nacional de Cancerología)Clinical & Translational OncologyJuly 25, 202310.1007/s12094-023-03279-2Cited by 5SaveCiteExport RISWatch citationsRelated PapersAssociation between CD47 expression, clinical characteristics and prognosis in patients with advanced non‐small cell lung cancer|Cancer Medicine|2020|80Prevalence of pathogenic or likely pathogenic germline variants in cancer predisposition genes among selected patients with lung adenocarcinoma: The GERMLUNG study|Lung Cancer|2024|7